Cyramza

Adult Dosing .

Dosage forms:  INJ

Special Note

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments; D/C 28 days before elective surgery, restart >2wk after major surgery when wound fully healed

gastric CA, advanced or metastatic

[8 mg/kg/dose IV q2wk]

Info: for pts w/ gastric or gastroesophageal junction adenocarcinoma w/ dz progression on or after fluoropyrimidine- or platinum-containing chemo; use as monotherapy or w/ paclitaxel

non-small cell lung CA, metastatic

[first-line tx]

Dose: 10 mg/kg/dose IV q2wk; Info: for pts w/ EGFR exon 19 deletions or exon 21 (L858R) substitution mutations; use w/ erlotinib

[progressive dz]

Dose: 10 mg/kg/dose IV x1 on day 1 of 21-day cycle; Info: for pts w/ dz progression on or after platinum-based chemo; use w/ docetaxel

colorectal CA, progressive metastatic

[8 mg/kg/dose IV q2wk]

Info: for pts w/ dz progression on or after bevacizumab, oxaliplatin, and a fluoropyrimidine; use w/ FOLFIRI as part of multi-drug chemo regimen

hepatocellular CA

[8 mg/kg/dose IV q2wk]

Info: for pts w/ dz progression on or after sorafenib and w/ alpha fetoprotein 400 ng/mL or greater

renal dosing

[see below]

CrCl >15: no adjustment; CrCl <15: not defined

HD/PD: not defined

hepatic dosing

[see below]

bilirubin 1.1-3x ULN or AST >ULN: no adjustment; bilirubin >3x ULN: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.